Lymphatic Imaging System

Description:

Market:  In 2009 there were approximately 1.5 million cases of cancer diagnosed in the United States alone.  Some portion of this patient population will develop lymphedemia due to damage to the lymphatic system from their treatment.   This condition is characterized by fibrosis from localized fluid retention and tissue swelling.  Some clinics currently treat lymphedemia with sequential grade pump therapy or specialized garments; however, as with any condition, an early indication of who will and will not develop lymphedemia may allow more time to provide specialized treatments in advance of symptom development.  Patents and practitioners need systems that will provide clear and reliable images of the lymphatic system for determination of problems.

 

Competitors and Current Problems:  The lymphatic imaging systems on the market today typically use a specialized dye and a device to image the dye; however, all of these systems have one of several drawbacks related to either the dye or the camera.  Additionally, there is frequently a lag time between imaging and resolution, and, often, the systems are unable to provide flow images showing the actual course of lymph through the tissue.  These flow images are critical to practitioners for determination of why and how lymphedemia is developing in a specific way. 

 

The Technology:   Dr. Eva Sevick and her collaborators have developed an extensive patent portfolio aimed at overcoming the deficiencies in existing lymphatic system imaging methods.  Her system provides real time images of the lymphatic system by making use not of expensive CT scanners or PET imagers, but of less expensive specialized cameras.  Additionally, through specifically modified dyes, Dr. Sevick’s system is able to use dosing levels significantly below those of her competitors.  By way of example, in clinical use, Dr. Sevick’s imaging system has diagnosed early lymphedemia in patients who would not have otherwise been diagnosed.  For the patients this means earlier treatment and avoidance of pain and more expensive measures. 

 

International Innovation* recently published an article on Dr. Sevick's Technology, a copy of which can be found here

 

Non-confidential Technology description

 

The preceding is intended to be a non-confidential summary of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth), for which the University has obtained patent protection. 

 

UTHealth Ref. No.: 2010-0064; 2010-0065 and more

Lead Inventor: Dr. Eva Sevick (http://www.uthouston.edu/imm/centers/molecular-imaging.htm)

Patent Status: 4 issued United States Patents, eight issued foreign patents, various pending United States and Foreign applications

License Available:  world-wide; exclusive or non-exclusive

 

To obtain further information about this technology, please contact:

Office of Technology Management, 7000 Fannin, Suite 720, Houston, TX, 77030

Phone: (713) 500-3369 Fax: (713) 500-0331

Email: uthsch-otm@uth.tmc.edu

 

*International Innovation is the leading global dissemination resource for the wider scientific, technology and research communities, dedicated to disseminating the latest science, research and technological innovations on a global level. More information and a complimentary subscription offer to the publication can be found at: www.researchmedia.eu

Patent Information:
For Information, Contact:
Christine Flynn
Assistant Director, New Venture Development
University of Texas Health Science Center At Houston
Christine.Flynn@uth.tmc.edu
Inventors:
Keywords:
© 2012. All Rights Reserved. Powered by Inteum